Deutsche Bank’s First Tracks Biotherapeutics TRAX Stock Holding History

Deutsche Bank’s Portfolio TRAX Stock Details TRAX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.25M	Buy	+62,117	New	+$1.16M	﹤0.01%	2212

Other funds holding TRAX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Sanofi Paris, France $534M AUM 205.96% 1-Year Est. Return

FEG

Financial Enhancement Group Anderson, Indiana $839M AUM 18.63% 1-Year Est. Return

Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

MAP

Moody Aldrich Partners Marblehead, Massachusetts $557M AUM 122.79% 1-Year Est. Return

Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return

Citigroup New York $303B AUM 53.02% 1-Year Est. Return

Tema ETFs New York $3.09B AUM 72.72% 1-Year Est. Return

YIH

Y-Intercept (HK) Hong Kong $5.05B AUM 17.89% 1-Year Est. Return

Russell Investments Group London, United Kingdom $114B AUM 41.71% 1-Year Est. Return

Deutsche Bank's TRAX Position: Q2 2026 in Review

Deutsche Bank opened a new position in First Tracks Biotherapeutics (TRAX) in Q2 2026: 62,117 shares worth $1.25M. The stake represents ﹤0.01% of the portfolio and ranks #2212 among its holdings.

38 funds tracked by Wall St. Rank hold TRAX as of Q2 2026.

Deutsche Bank held 62,117 shares of First Tracks Biotherapeutics worth $1.25M as of Q2 2026.
First Tracks Biotherapeutics was a new Deutsche Bank position in Q2 2026.
First Tracks Biotherapeutics made up ﹤0.01% of Deutsche Bank's portfolio in Q2 2026, its #2212 holding.
38 funds tracked by Wall St. Rank held First Tracks Biotherapeutics as of Q2 2026.

Based on Deutsche Bank's 13F filing for Q2 2026, filed 7 Aug 2026.